Jin Yang1, Salem Dehom2, Stephanie Sanders3, Thomas Murry4, Priya Krishna4, Brianna K Crawley4. 1. Loma Linda University School of Medicine, Loma Linda, CA, USA. Electronic address: jiyang@llu.edu. 2. Loma Linda University School of Public Health, Loma Linda, CA, USA. 3. Loma Linda University School of Medicine, Loma Linda, CA, USA. 4. Voice and Swallowing Center-Loma Linda University Medical Center, Loma Linda, CA, USA.
Abstract
OBJECTIVE: To determine if an anti-reflux induction program relieves laryngopharyngeal reflux (LPR) symptoms more effectively than medication and behavioral changes alone. STUDY DESIGN: Retrospective study. SETTING: Tertiary care academic center. SUBJECTS AND METHODS: A database was populated with patients treated for LPR. Patients were included in the study group if they completed a two-week anti-reflux program (diet, alkaline water, medications, behavioral modifications). Patients were included in the control group if they completed anti-reflux medications and behavioral modifications only. Patients completed the voice handicap index (VHI), reflux symptom index (RSI), cough severity index (CSI), dyspnea index (DI) and eating assessment tool (EAT-10) surveys and underwent laryngoscopy for examination and reflux finding score (RFS) quantification. RESULTS: Of 105 study group patients, 96 (91%) reported subjective improvement in their LPR symptoms after an average 32-day first follow-up and their RSI and CSI scores improved significantly. No significant differences were found in VHI, DI, or EAT-10 scores. Fifteen study patients who had previously failed adequate high-dose medication trials reported improvement and their CSI and EAT-10 scores improved significantly. Ninety-five percent of patients with a chief complaint of cough reported improvement and their CSI scores improved significantly from 12.3 to 8.2. Among 81 controls, only 39 (48%) patients reported improvement after an average 62-day first follow-up. Their RSI scores did not significantly change. CONCLUSION: The anti-reflux program yielded rapid and substantial results for a large cohort of patients with LPR. It compared favorably with medication and behavioral modification alone. It was effective in improving cough and treating patients who had previously failed medications alone.
OBJECTIVE: To determine if an anti-reflux induction program relieves laryngopharyngeal reflux (LPR) symptoms more effectively than medication and behavioral changes alone. STUDY DESIGN: Retrospective study. SETTING: Tertiary care academic center. SUBJECTS AND METHODS: A database was populated with patients treated for LPR. Patients were included in the study group if they completed a two-week anti-reflux program (diet, alkaline water, medications, behavioral modifications). Patients were included in the control group if they completed anti-reflux medications and behavioral modifications only. Patients completed the voice handicap index (VHI), reflux symptom index (RSI), cough severity index (CSI), dyspnea index (DI) and eating assessment tool (EAT-10) surveys and underwent laryngoscopy for examination and reflux finding score (RFS) quantification. RESULTS: Of 105 study group patients, 96 (91%) reported subjective improvement in their LPR symptoms after an average 32-day first follow-up and their RSI and CSI scores improved significantly. No significant differences were found in VHI, DI, or EAT-10 scores. Fifteen study patients who had previously failed adequate high-dose medication trials reported improvement and their CSI and EAT-10 scores improved significantly. Ninety-five percent of patients with a chief complaint of cough reported improvement and their CSI scores improved significantly from 12.3 to 8.2. Among 81 controls, only 39 (48%) patients reported improvement after an average 62-day first follow-up. Their RSI scores did not significantly change. CONCLUSION: The anti-reflux program yielded rapid and substantial results for a large cohort of patients with LPR. It compared favorably with medication and behavioral modification alone. It was effective in improving cough and treating patients who had previously failed medications alone.
Authors: Jerome R Lechien; Francois Bobin; Francois Mouawad; Karol Zelenik; Christian Calvo-Henriquez; Carlos M Chiesa-Estomba; Necati Enver; Andrea Nacci; Maria Rosaria Barillari; Antonio Schindler; Lise Crevier-Buchman; Stéphane Hans; Virginie Simeone; Elzbieta Wlodarczyk; Bernard Harmegnies; Marc Remacle; Alexandra Rodriguez; Didier Dequanter; Pierre Eisendrath; Giovanni Dapri; Camille Finck; Petros Karkos; Hillevi Pendleton; Tareck Ayad; Vinciane Muls; Sven Saussez Journal: Eur Arch Otorhinolaryngol Date: 2019-09-12 Impact factor: 2.503
Authors: Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati Journal: Ann N Y Acad Sci Date: 2021-12-17 Impact factor: 6.499
Authors: Michał Wiciński; Bartosz Malinowski; Oskar Puk; Karol Górski; Dawid Adamkiewicz; Grzegorz Chojnacki; Maciej Walczak; Eryk Wódkiewicz; Monika Szambelan; Paulina Adamska; Kamila Skibińska; Maciej Socha; Maciej Słupski; Katarzyna Pawlak-Osińska Journal: Biomed Res Int Date: 2019-10-17 Impact factor: 3.411
Authors: Jerome R Lechien; Francois Mouawad; Maria R Barillari; Andrea Nacci; Seyyedeh Maryam Khoddami; Necati Enver; Sampath Kumar Raghunandhan; Christian Calvo-Henriquez; Young-Gyu Eun; Sven Saussez Journal: World J Clin Cases Date: 2019-10-06 Impact factor: 1.337